While it is today in many ways a new company ��new CEO, new ticker symbol, many of its old legacy expenses wiped away with its bankruptcy ��it still remains a work in progress toward that profitability goal.
The iconic Rochester, N.Y.-based company put out its fourth-quarter 2013 and 2013 overall financial results Wednesday after the market's close. The printing technology company's losses were far smaller than in the previous year. And its expectations for 2014 put it close to ��though still not at ��profitability.
STORY: Kodak names Clarke new CEO
STORY: Kodak CEO outlines growth strategy
Top 10 Tech Stocks To Buy For 2015: RigNet Inc.(RNET)
RigNet, Inc. provides remote communications services for the oil and gas industry. It offers remote communications services through a controlled and managed Internet protocol/multiprotocol label switching (IP/MPLS) global network, enabling drilling contractors, oil companies, and oilfield service companies to communicate. The company offers a communications package of voice, data, video, networking, and real-time data management to offshore and land-based remote locations. It primarily provides voice-over-Internet-protocol, data, and high-speed Internet access, as well as other value-added services, such as video conferencing solutions, TurboNet solutions for wide area network, real-time data management solutions, Wi-Fi hotspots and Internet kiosks, wireless intercoms, and handheld radios. The company also offers Secure Oil Information Link, a managed members-only communications network hub that enables collaborative partners, suppliers, and customers to transfer and share data. It serves the owners and operators of offshore drilling rigs and production facilities, land rigs, remote offices, and supply bases primarily in the United States, Brazil, Norway, the United Kingdom, Nigeria, Qatar, Saudi Arabia, Singapore, and Australia. The company was founded in 2000 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on RigNet (Nasdaq: RNET ) , whose recent revenue and earnings are plotted below.
Top 10 Tech Stocks To Buy For 2015: Tencent Holdings Ltd (TCTZF)
Tencent Holdings Limited is an investment holding company. The Company and its subsidiaries are principally engaged in the provision of Internet value-added services, mobile and telecommunications value-added services and online advertising services to users in the People�� Republic of China. The Company operates in four segments: Internet value-added services, Mobile and telecommunications value-added services, Online advertising, and Others. As of December 31, 2011, its subsidiaries included Tencent Cyber (Tianjin) Company Limited, Tencent Asset Management Limited, Tencent Technology (Beijing) Company Limited, Tencent Cyber (Shenzhen) Company Limited, Tencent Technology (Shanghai) Company Limited and others. Advisors' Opinion:- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Chinese stocks fell early Wednesday, joining a broadly negative day for regional trade in the wake of overnight losses on Wall Street. Hong Kong's Hang Seng Index (HK:HSI) dropped by 0.5% to 23,625.77, with the Hang Seng China Enterprises Index 0.8% lower, while the Shanghai Composite (CN:SHCOMP) fell 0.7%. Top-weighted Hang Seng component HSBC Holdings PLC (HK:5) fell 0.5%, while fellow international lender Standard Chartered PLC (HK:2888) (UK:STAN) lost 1.4%, with some reports linking the losses to the approval of the so-called Volcker rule in the U.S. which prohibits most proprietary trading by banks there. The Financial Times also cited concerns about possible cash-calls as weighing on Standard Chartered. Meanwhile, ratings moves influenced some shares. Jiangxi Copper Co. (HK:358) (JIXAY) retreated 1%, and China Shenhua Energy Co. (HK:1088) (CUAEF) dropped 1.4% after Credit Suisse cut both stocks to neutral, according to Kim Eng Securities. However, Tencent Holdings Ltd. (HK:700) (TCTZF) added 1.5% to its price after Deutsche Bank upped the Internet content provider's rating to buy. Also bucking the downtrend, China Overseas Land & Investment Ltd. (HK:688) (CAOVF) gained
Hot Clean Energy Stocks To Watch For 2015: Accelrys Inc.(ACCL)
Accelrys, Inc. develops and commercializes scientific business intelligence software and solutions in the United States, Europe, and the Asia Pacific. The company offers Pipeline Pilot, Accelrys enterprise R&D platform, which allows users to aggregate, integrate, and mine structured and unstructured scientific data, such as chemical structures, biological sequences, and complex digital images; and filters, normalizes, and performs statistical analysis on the scientific data and provides visual reports to scientists and scientific managers. It also provides computer aided design modeling and simulation software that allows scientists to perform computations of chemical, biological, and materials properties to simulate, visualize, and analyze chemical and biological systems, as well as communicate the results to other scientists; and data management and informatics software to capture, store, manage, and mine scientific data information. In addition, the company offers Enter prise Lab Notebook, which provides a digital environment to plan, execute, record, store, back-up, and share daily research activities; lab execution systems; and content databases to support research activities through a collection of factual databases and reference works. Further, it provides software wrappers that allows customers to run their own algorithms on the company?s R&D platform; enterprise-wide informatics systems, which integrate customers? internal systems with software from various vendors; contract research services; onsite training and implementation, Web-based training, and data migration services; and support services. The company serves pharmaceutical, biotechnology, agricultural, energy, chemicals, aerospace, consumer packaged goods, and industrial product industries, as well as government and academic entities through direct sales force, telesales, and distributors. Accelrys, Inc. was founded in 1993 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Alex Planes]
What: Shares of Accelrys (NASDAQ: ACCL ) are down by over 20% today after the company took a big, ugly swing and a miss on its first-quarter earnings and upcoming guidance.
Top 10 Tech Stocks To Buy For 2015: Biogen Idec Inc(BIIB)
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
Elan (NYSE: ELN )
Having a lot of cash in the biotech sector doesn't mean that a company's clinical trials will translate into success. Elan's claim to fame was the development of multiple sclerosis drug Tysabri, which it licensed out to Biogen Idec (NASDAQ: BIIB ) . Sales of the drug hit $1.6 billion last year. - [By Brian Orelli]
APD334 targets the sphingosine 1-phosphate subtype 1 receptor, which is involved in numerous autoimmune diseases, including multiple sclerosis, psoriasis, and rheumatoid arthritis. All three diseases are large markets with multiple blockbuster drugs treating them. Biogen Idec (NASDAQ: BIIB ) , for instance, has two multiple sclerosis drugs -- Avonex and Tysabri -- that are both blockbusters. AbbVie's (NYSE: ABBV ) Humira, which treats both psoriasis and rheumatoid arthritis, posted sales of more than $9.2 billion last year.
- [By Ben Levisohn]
Shares of Gilead Sciences have ticked up 0.1% to $73.69 at 1:58 p.m. today, a solid day given Amen’s (AMGN) 0.7% drop to $125.53 and Biogen Idec’s (BIIB) 0.7% decline to $307.76.The iShares Nasdaq Biotechnology ETF (IBB) has fallen 0.5% to $240.34, while the SPDR S&P Biotech ETF (XBI) has dropped 1.2% to $1434.68.
Top 10 Tech Stocks To Buy For 2015: Actelion Ltd (ATLN.VX)
Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of iloprost, and Zavesca, an oral treatment for type 1 Gaucher disease. Furthermore, the Company has a number of compounds various stages of development. The Company operates through a number of worldwide subsidiaries, including Actelion Registration Ltd, which holds marketing authorizations for products marketed in the European Union; Actelion Clinical Research, Inc, engaged in clinical development on behalf of the Company's group; Actelion Re SA, providing insurance solutions for the Company's group and Actelion US Holding Company, engaged in the holding activities of the Company's United States-based units. In September 2013, it acquired Ceptaris Therapeutics, Inc. Advisors' Opinion:- [By Victor Selva]
Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.
Top 10 Tech Stocks To Buy For 2015: Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company�� ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs. The Company�� two advanced cancer programs are targeting mutations in the enzymes isocitrate dehydrogenase 1 and 2, referred to as IDH1 and IDH2. The Company�� drug candidates are selective for the mutated forms of IDH1 and IDH2 found in cancer cells versus the normal forms of IDH1 and IDH2 found in all other cells.
The Company focused on developing medicines to address IEMs, with a novel approach to these orphan diseases for which no effective or disease-modifying therapy is available. The Company has also de-validated and terminated numerous programs, including many that have been reported in scientific journals. In the Company�� IEM portfolio, it uses an equally rigorous set of validation techniques.
Advisors' Opinion:- [By Roberto Pedone]
Another stock that insiders are moving into here is Agios Pharmaceuticals (AGIO), which focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism in the U.S. Insiders are buying this stock into major strength, since shares are up big so far in 2014 by 79%.
Agios Pharmaceuticals has a market cap of $1.4 billion and an enterprise value of $1.5 billion. This stock trades at a premium valuation, with a price-to-sales of 53.91 and a price-to-book of 11.51. Its estimated growth rate for this year is 48.1%, and for next year it's pegged at 15%. This is a cash-rich company, since the total cash position on its balance sheet is $162.27 million and its total debt is zero.
A director just bought 2,300 shares, or about $100,000 worth of stock, at $43.98 per share.
From a technical perspective, AGIO is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been selling off after a failed breakout attempt for the last few weeks, with shares moving lower from its high of $50.37 to its intraday low of $42.15 a share. That move is quickly pushing shares of AGIO within range of tagging its 50-day moving average of $40.27 a share.
If you're bullish on AGIO, then I would look for long-biased trades as long as this stock is trending above its 50-day at $40.27 and then once it breaks out above some near-term overhead resistance at $45 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 419,691 shares. If that breakout starts soon, then AGIO will set up to re-test or possibly take out its next major overhead resistance level at its all-time high of $50.37 a share. Any high-volume move above that level will then give AGIO a chance to tag $55 to $60 a share.
Top 10 Tech Stocks To Buy For 2015: Akamai Technologies Inc.(AKAM)
Akamai Technologies, Inc. provides content delivery and cloud infrastructure services for accelerating and improving applications over the Internet in the United States and internationally. The company offers application and cloud performance solutions to enhance the operation of the applications used by enterprises to connect with their employees, suppliers, and customers. Its solutions include Web Application Accelerator, which enables enterprises to run various applications; and IP Application Accelerator that is designed to optimize the performance, availability, and real-time sensitivity associated with IP-enabled applications delivered over Internet-related protocols. The company also provides video and software solutions that are designed to enable enterprises to execute their large file management and distribution strategies, which include media delivery solution to entertainment industry; and electronic software delivery solution that handles the distribution of s oftware for its customers. In addition, it offers Website optimization services for accelerating business-to-consumer Websites that integrate collaborative content and applications into their online architecture; security and protection solutions that address the Internet security requirements; and network operator solutions, which provide custom solutions to commercial and government customers. Further, the company provides mobile content adaptation solution; and advertising decision solutions that enable advertisers, agencies, publishers, and networks to buy and sell advertising, as well as network data feeds, Website analytics, and business performance management services. It markets and sells its services and solutions through direct sales and services organization; and through active channel partners. Akamai Technologies, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Tim Beyers]
Akamai Technologies (NASDAQ: AKAM ) soared as much as 21% as the leading content delivery network served more online media traffic than expected. Both revenue and earnings easily topped estimates.
- [By Alex Planes]
How many times have you heard (or said) that computer programming seems like a pretty great job? Many of the best companies to work for are major employers of software engineers. The Fool's own list of the 25 best companies in America has three: Google (NASDAQ: GOOG ) , Akamai (NASDAQ: AKAM ) , and IBM. Google and Akamai also place highly on Glassdoor's latest Best Places to Work list, which is topped by Facebook (NASDAQ: FB ) , one of the few companies to inspire an award-winning film about (among other things) coding software.
- [By Sue Chang and Ben Eisen]
Akamai Technologies Inc. (AKAM) �shares surged 20% after the technology company said late Wednesday that its fourth-quarter profit rose over 18% as revenue jumped. The company, which runs a network of services and equipment to speed up the delivery of online content, has grown substantially in recent years.
- [By Rick Munarriz]
Briefly in the news
Cliffs Natural Resources (NYSE: CLF ) moved higher after posting results that may not seem all that inspiring at first. Revenue slipped 6% and adjusted earnings plunged 74% . However, the iron ore pellets producer was expected to each just half as much as it did. After seeing its stock shed nearly roughly half of its value this year, the bounce was more than overdue. Akamai (NASDAQ: AKAM ) also posted better-than-expected results, proving that being a content delivery network doesn't have to be a cutthroat business. J.P. Morgan upgraded Akamai on the strong report. Baidu (NASDAQ: BIDU ) was a rare tech loser on the week, slipping on Friday after posting a quarterly profit that fell well short of Wall Street's forecast. Sometimes even a stock trading at an earnings multiple in the teens yet sporting net profit margins of 34% and growing revenue at a 40% clip isn't good enough.
And now let's take a quick look at some of the other stories that shaped our week.
Top 10 Tech Stocks To Buy For 2015: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.
The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.
CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.
Advisors' Opinion:- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
- [By John Kell]
Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.
Top 10 Tech Stocks To Buy For 2015: Worlds Inc (WDDD.OB)
Worlds Inc., (Worlds.com), incorporated on April 26, 1994, was a three-dimensional (3D) entertainment portal, which leveraged its technology, which the Company retained through its portfolio, to offer visitors a network of virtual, multi-user environments which the Company calls worlds. On May 16, 2011, the Company transferred, through a spin-off to its wholly owned subsidiary, Worlds Online Inc., the majority of its operations and related operational assets. The Company designs and develops software, content and related technology for the creation of interactive, three-dimensional (3D) Internet Web sites. The Company used its technology to produce three-dimensional portals and Web sites. The Company's core technology includes WorldsShaper, WorldsServer, WorldsBrowser, WorldsPlayer and Worlds Gamma Libraries.
WorldsShaper is the visual authoring component of the Company's platform. It allows for quick assembly of pieces to create multi-user, shared state, virtual worlds. The WorldsShaper is an advanced compositing 3D building tool that integrates pre-existing or custom content, such as 3D models, textures or images created in Adobe's Photoshop, or midi or wave sound files, with architectural geometry and interactive behaviors and actions written in Java. WorldsServer is the scalable software that the Company uses to control and operates its on-line virtual communities. WorldsServer manages the registration and authentication of users, the locations of users within the 3D environment, the physical structure of the 3D environment, all information regarding objects that are shared by the participants and any of the interactions between the users such as text chat. This platform also integrates an HTTP server for the delivery of other content such as audio and video streaming and secure e-commerce applications.
WorldsBrowser is used to access the 3D environments. The browser is optimized for speed, delivering relatively fast frame rates per second in textured virtual 3D worlds. T! he WorldsPlayer allows users to view and experience the Company's multi-user, interactive technology. Any world created with the WorldsShaper will be viewable and navigable with the WorldsPlayer. The Worlds Gamma Libraries are consists of sample worlds, textures, models, avatars, actions, sensors, sounds, motion sequences, and other behaviors.
Advisors' Opinion:- [By Markman Advisors]
Public companies leveraging their patent portfolios, (aka "patent plays"), are getting the market's attention. Companies such as Vringo (VRNG), ParkerVision (PRKR), MGT Capital (MGT), Worlds Inc. (WDDD.OB) and others have presented trading opportunities due to their volatility while retaining the chance for a big payoff to those investors who stay the course. Yet there exist viable patent plays that are still undiscovered. Some of these so called "plays," which are not getting enough attention, are actually real companies making and selling real products or services in contrast to pure patent monetization companies. Some known examples are Single Touch Interactive (SITO.OB) and Blue Calypso (BCYP.OB). This article is focused on another one of these patent plays, On Track Innovations Ltd. (OTIV).
Top 10 Tech Stocks To Buy For 2015: Intercept Pharmaceuticals Inc (ICPT)
Intercept Pharmaceuticals, Inc., incorporated on September 4, 2002, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�� product candidates treat orphan and more prevalent liver diseases for which there are limited therapeutic solutions. The Company�� product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.
The Company�� clinical focus is on the development of OCA, orally administered, first-in-class FXR agonist that has broad liver-protective properties and may a variety of chronic insults to the liver that cause fibrosis, which can eventually lead to cirrhosis, liver transplant and death. The Company owns worldwide rights to OCA outside of Japan and China, where it has licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to license OCA in certain other Asian countries.The Company is sponsoring an independent study involving more than ten leading PBC centers in North America and Europe, or collectively the Global PBC Study Group, that are pooling their long-term patient data to evaluate the relationship between biochemical and clinical endpoints.
The Company competes with Eli Lilly, Exelixis, Inc., Phenex Pharmaceuticals AG, , Johnson & Johnson, NovImmune SA, Dr. Falk Pharma GmbH, Galmed Medical Researc! h Ltd., Immuron Ltd., Mochida Pharmaceutical Co., Ltd., NasVax Ltd. , Raptor Pharmaceutical Corp. Astellas Pharma US, Inc., AstraZeneca, Salix Pharmaceuticals, Inc. and Tioga Pharmaceuticals, Inc.
Advisors' Opinion:- [By Sue Chang and Ben Eisen]
Shares of Intercept Pharmaceuticals Inc. (ICPT) �soared another 62% following a surge of 281% on Thursday. The company announced on Thursday that halted the trial of its obeticholic acid drug to treat nonalcoholic steatohepatitis (NASH) ahead of schedule on positive results. The drug could be the first reliable treatment option for patients facing liver transparent and as a result, obeticholic acid could be a true blockbuster, according to Jim Molloy, an analyst at Janney Capital Markets.
No comments:
Post a Comment